- Home
- WOK vs MYNZ Comparison
WOK vs MYNZ Comparison
Compare WOK & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- MYNZ
- Stock Information
- Founded
- WOK 2002
- MYNZ 2021
- Country
- WOK China
- MYNZ Germany
- Employees
- WOK N/A
- MYNZ N/A
- Industry
- WOK
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- MYNZ Health Care
- Exchange
- WOK NYSE
- MYNZ Nasdaq
- Market Cap
- WOK 9.3M
- MYNZ 10.5M
- IPO Year
- WOK 2024
- MYNZ 2021
- Fundamental
- Price
- WOK $0.57
- MYNZ $2.93
- Analyst Decision
- WOK
- MYNZ Buy
- Analyst Count
- WOK 0
- MYNZ 3
- Target Price
- WOK N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- WOK 227.5K
- MYNZ 174.9K
- Earning Date
- WOK 02-03-2025
- MYNZ 04-15-2025
- Dividend Yield
- WOK N/A
- MYNZ N/A
- EPS Growth
- WOK N/A
- MYNZ N/A
- EPS
- WOK N/A
- MYNZ N/A
- Revenue
- WOK $11,506,440.00
- MYNZ $917,203.00
- Revenue This Year
- WOK N/A
- MYNZ $20.94
- Revenue Next Year
- WOK N/A
- MYNZ $18.01
- P/E Ratio
- WOK N/A
- MYNZ N/A
- Revenue Growth
- WOK N/A
- MYNZ 16.23
- 52 Week Low
- WOK $0.50
- MYNZ $0.18
- 52 Week High
- WOK $8.45
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- MYNZ 29.69
- Support Level
- WOK N/A
- MYNZ $4.06
- Resistance Level
- WOK N/A
- MYNZ $5.34
- Average True Range (ATR)
- WOK 0.00
- MYNZ 0.53
- MACD
- WOK 0.00
- MYNZ -0.14
- Stochastic Oscillator
- WOK 0.00
- MYNZ 7.66
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.